US Dollar Rises Early Thursday Ahead of Jobless Claims, Wholesale Inventories
MT newswire2026/10/08 11:5407:54 AM EDT, 10/08/2026 (MT Newswires) -- The US dollar rose against its major trading partners early Thursday ahead of the release of weekly jobless claims data at 8:30 am ET and wholesale inventories data for August at 10:00 am ET. Weekly natural gas stocks data are due to be released at 10:30 am ET and the Atlanta Federal Reserve is expected to update its GDP nowcast estimate around midday. A quick summary of foreign exchange activity heading into Thursday: EUR/USD fell to 1.1176 from 1.1198 at the Wednesday US close and 1.1190 at the same time Wednesday morning. There are no Eurozone data on Thursday's schedule. The next European Central Bank meeting is scheduled for Oct. 29. GBP/USD fell to 1.3193 from 1.3211 at the Wednesday US close and 1.3213 at the same time Wednesday morning. There are no UK data on Thursday's schedule, but Bank of England Governor Andrew Bailey is due to speak at 8:15 am ET. The next Bank of England meeting is scheduled for Nov. 5. USD/JPY rose to 158.2751 from 158.0832 at the Wednesday US close but was below a level of 158.3361 at the same time Wednesday morning. The Bank of Japan current account surplus widened in August while services business sentiment improved in September. The next Bank of Japan meeting is scheduled for Oct. 30. USD/CAD rose to 1.4273 from 1.4262 at the Wednesday US close and 1.4241 at the same time Wednesday morning. There are no Canadian data on Thursday's schedule. The next Bank of Canada meeting is scheduled for Oct. 28.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
Crypto prices
More
